PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩80 per share · Prices as of the 2026-10-02 close
Sinsin Pharmaceutical is seeing step-by-step operating margin improvement in its patch-centered business while attempting to diversify growth drivers through CDMO expansion, microneedle technology, and overseas markets.
Revenue rose every year from 2022 to 2025, with operating margin improving step-by-step from 5.9% to 9.5%.
Flagship brand Sinsin Pas Arex ranked No.1 in the anti-inflammatory analgesic category of the Korea Brand Power Index (K-BPI) for the eighth consecutive year as of March 2026.
A Phase 3 clinical trial for overactive bladder treatment candidate UIP620 was voluntarily discontinued in May 2026.
The company is pursuing overseas expansion, including a cross-border e-commerce supply agreement with China's Sinopharm and new market development in the Middle East and Latin America.
The debt ratio declined from 103.6% in 2022 to 84.5% in 2025, indicating gradual improvement in the balance sheet.
Founded in 1959, Sinsin Pharmaceutical launched Korea's first medicated patch and has since accumulated transdermal drug delivery system (TDDS) technology as a specialty topical-medicine maker.
Its core business is transdermal patches, which accounted for 53.4% of revenue in the first quarter of 2026 and made up more than half of total revenue in 2025.
Its flagship brand, Sinsin Pas Arex, ranked No.1 in the anti-inflammatory analgesic category of the Korea Brand Power Index (K-BPI) for the eighth consecutive year as of March 2026.
Beyond patches, the company is regarded as the only domestic maker producing the full lineup of topical anti-inflammatory analgesic formulations in-house, including topical liquids (16.6% of first-quarter revenue), oral formulations (11.1%), ointments (7.5%), and aerosols (4.2%).
By sales channel, pharmacies accounted for the largest share at 48.1%, followed by pharmaceutical wholesalers (22.8%) and distribution vendors (13.3%). After relocating its production base from Ansan to Sejong in 2020, the company introduced automation equipment that has improved its cost structure.
More recently it has been expanding its contract manufacturing (CMO) business into contract development and manufacturing (CDMO) and diversifying its technology portfolio with dissolving microneedle-based arthritis treatments.
Exports accounted for 14.5% of total revenue in the first quarter of 2026, and the company is pursuing a cross-border e-commerce supply agreement with China's Sinopharm along with market development in the Middle East and Latin America.
Within a competitive landscape led by a small number of players with in-house manufacturing capacity and brand strength, Sinsin Pharmaceutical maintains its position by holding both attributes simultaneously.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩29.6B | ₩2.2B | 7.5% |
| 2025Q3 | ₩30.1B | ₩4B | 13.1% |
| 2025Q4 | ₩28.8B | ₩3.3B | 11.6% |
| 2026Q1 | ₩30.2B | ₩3.2B | 10.5% |
| 2026Q2 | ₩34B | ₩4.1B | 12.0% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩91.9B | ₩5.4B | ₩4.4B | 5.9% | 7.4% | 103.6% |
| 2023 | ₩102.6B | ₩6B | ₩4.7B | 5.9% | 7.5% | 100.4% |
| 2024 | ₩106.4B | ₩6.9B | ₩4.9B | 6.5% | 7.4% | 97.5% |
| 2025 | ₩113.8B | ₩10.8B | ₩9.3B | 9.5% | 12.4% | 84.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-22
Sinsin Pharmaceutical's 2025 consolidated revenue reached KRW 113.78 billion, up from KRW 106.39 billion a year earlier, while operating profit surged to KRW 10.79 billion from KRW 6.89 billion, lifting the operating margin from 6.5% to 9.5%.
Net income attributable to controlling shareholders also rose from KRW 4.89 billion to KRW 9.29 billion, marking a clear earnings improvement.
From 2022 to 2025, revenue climbed each year from KRW 91.9 billion to KRW 102.6 billion, KRW 106.4 billion, and KRW 113.8 billion, while the operating margin advanced step-by-step from 5.9% to 5.9%, 6.5%, and 9.5%.
The introduction of automation equipment and process improvements at the Sejong plant, along with additional employment incentives received from the Sejong city government, are cited as key drivers of the 2025 profit improvement.
On a quarterly basis, third-quarter 2025 operating profit jumped to KRW 3.96 billion from KRW 2.22 billion in the second quarter, and remained elevated at KRW 3.34 billion in the fourth quarter.
In 2026, operating profit reached KRW 3.18 billion in the first quarter (a 10.5% margin) and KRW 4.06 billion in the second quarter (an 11.9% margin), showing that margin gains accompanied revenue growth.
Net income attributable to controlling shareholders stayed at a stable level across quarters: KRW 3.42 billion in the third quarter of 2025, KRW 3.50 billion in the fourth quarter, KRW 2.86 billion in the first quarter of 2026, and KRW 3.68 billion in the second quarter.
Combined net income attributable to controlling shareholders over the most recent four quarters (Q3 2025 through Q2 2026) totaled KRW 13.47 billion, indicating that the annualized profit level has moved up a notch from the prior year.
On the cash flow side, operating cash flow rose from KRW 5.46 billion in 2022 to KRW 8.58 billion in 2025, suggesting the quality of earnings has improved alongside reported profit.
Korea's over-the-counter (OTC) transdermal patch market is understood to be led by a small number of players with in-house manufacturing capacity and brand strength.
Across the broader domestic pharmaceutical industry, drug price cuts and intensifying competition have pressured the profitability of prescription-drug-focused companies, prompting many small and mid-sized pharmaceutical firms to diversify their businesses and R&D strategies.
Companies like Sinsin Pharmaceutical, which are centered on OTC and topical formulations, are relatively insulated from the direct impact of drug price cuts, but face the structural limitation that the domestic market itself does not grow rapidly.
According to market researcher Global Market Insights, the global pain-relief patch market was valued at roughly $3.9 billion in 2023 and is projected to grow at a compound annual rate of 6.2% through 2032, driven by rising sports participation and a growing population of chronic pain patients due to aging.
The broader domestic biohealth industry has been riding an export expansion trend, with biopharmaceutical exports in the first half of 2026 rising 15.3% year-on-year to a provisional $4.5 billion, extending an over-20% average annual growth streak over the past three years.
However, this export growth has been concentrated mainly in biosimilars and CDMO services, meaning the benefit to topical anti-inflammatory analgesics, Sinsin's core business, may be relatively limited.
Competitors include the patch lines of larger pharmaceutical companies and specialized contract manufacturers, and Sinsin Pharmaceutical points to its in-house production of the full lineup of topical anti-inflammatory analgesics as a key competitive advantage.
In its early-2025 New Year address, the company outlined plans to strengthen marketing centered on the Sinsin Pas Flex series, expand its existing contract manufacturing (CMO) business into contract development and manufacturing (CDMO), and create new overseas business opportunities in regions such as the Middle East and Latin America.
On the microneedle front, there are signs of an effort to diversify the drug portfolio through development of a dissolving microneedle-based general arthritis treatment and related international patent filings.
However, a pipeline candidate for overactive bladder treatment, UIP620, had its Phase 3 clinical trial voluntarily withdrawn and discontinued as disclosed in May 2026. This illustrates that the plan to secure new growth drivers outside the patch business through drug development has faced some setbacks.
In China, the company continues to pursue market entry via online distribution channels under a five-year, $5.4 million cross-border e-commerce supply agreement with Sinopharm.
Separately, news related to a proposed bill on relocating the administrative capital drew market attention given the company's landholdings in Sejong.
The company's medium- to long-term growth story appears to hinge on how much revenue the new pillars of CDMO, microneedle technology, and overseas exports can eventually generate, built on top of its solid position in the domestic OTC market.
The current valuation metrics reflect much of the recent earnings improvement. The stock trades below its book value per share, placing it in a discounted range relative to net assets, and the price-to-earnings ratio calculated on the most recent four quarters of net income is also on the low side.
Cash dividends have been maintained each year, though the absolute dividend yield level is not particularly high. Given that the operating margin rose step-by-step from 5.9% in 2022 to 9.5% in 2025, it is worth tracking how valuation metrics are updated with each future earnings release.
Interpretation of these metrics may differ depending on whether the market views the recent profit improvement as driven by one-off factors or as a structural gain in profitability.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-22
Operating margin rose step-by-step from 5.9% in 2022 to 9.5% in 2025, and remained in double digits at 10.5% and 11.9% in the first and second quarters of 2026, respectively. Automation and process improvements at the Sejong plant are cited as key drivers behind the reduced cost ratio.
Operating cash flow also increased over the same period, indicating that the quality of earnings has improved alongside reported profit.
Sinsin Pas Arex ranked No.1 in the anti-inflammatory analgesic category of the K-BPI for the eighth consecutive year as of March 2026. The company is the only domestic maker producing the full lineup of topical anti-inflammatory analgesics in-house, combining brand strength with manufacturing competitiveness. Patches account for more than half of revenue, serving as a stable cash-generating core business.
The company is expanding its CMO business into CDMO while pursuing a cross-border e-commerce agreement with China's Sinopharm and new market development in the Middle East and Latin America.
Efforts to diversify the drug portfolio continue through development of a dissolving microneedle-based arthritis treatment and related international patent filings. However, these new businesses still account for a limited share of total revenue.
A Phase 3 clinical trial for overactive bladder treatment candidate UIP620 was voluntarily withdrawn and discontinued in May 2026. This adds uncertainty to plans to secure new growth drivers outside the patch business.
If results fail to materialize relative to development costs, questions could remain over the efficiency of R&D investment.
A substantial portion of company revenue comes from domestic OTC sales, and the growth rate of the domestic patch and topical-medicine market itself is considered limited. The overseas revenue share was just 14.5% in the first quarter of 2026, meaning it has not yet become an absolute overseas growth driver. A business structure heavily dependent on the domestic market could constrain the ceiling for top-line growth.
As a small-cap KOSDAQ stock with limited market capitalization, trading liquidity may be relatively constrained. The debt ratio declined from 103.6% in 2022 to 84.5% in 2025 but remains in the 80% range. If earnings improvement fails to continue, volatility in valuation metrics could increase.
Drug price cuts and intensifying competition are progressing across the domestic pharmaceutical industry, pressuring the profitability of prescription-drug-focused companies.
Sinsin Pharmaceutical faces limited direct impact given its OTC-centered structure, but broader policy shifts could still affect the industry as a whole. Continued monitoring of drug pricing policy changes is warranted.
As with the early termination of the UIP620 Phase 3 trial, drug pipelines carry an inherent risk of discontinuation or delay at the clinical stage.
The commercialization timeline for new technologies such as microneedles has not yet been concretely finalized, making it difficult to anticipate when investment returns might materialize.
The government stated that a second-half 2026 support program added preferential provisions for export companies affected by the prolonged conflict in the Middle East.
Sinsin Pharmaceutical's strategy of expanding into new export regions such as the Middle East and Latin America could see its progress affected by geopolitical variables.
The third-quarter 2026 report (quarterly report) is due for disclosure. This is a point to check whether the operating margin improvement and revenue growth trend continue.
It is worth checking for follow-up disclosures on the commercialization of the dissolving microneedle-based arthritis treatment and related international patent filings.
Monitor the progress of National Assembly deliberation on the proposed bill to relocate the administrative capital, a thematic issue linked to the value of the company's landholdings in Sejong.
Check the implementation status of the five-year agreement with China's Sinopharm and whether new export contracts are signed in regions such as the Middle East and Latin America.
Drawing on more than six decades of experience in the transdermal patch business, Sinsin Pharmaceutical maintains brand dominance in the domestic OTC anti-inflammatory analgesic market.
Revenue increased every year from 2022 to 2025, and the operating margin improved step-by-step from 5.9% to 9.5%, reflecting the impact of automation at the Sejong plant on results.
Revenue and operating profit continued to rise together in the first and second quarters of 2026, extending the earnings improvement trend, but the early termination of the Phase 3 clinical trial for overactive bladder treatment UIP620 illustrates the uncertainty involved in securing new growth drivers beyond the patch business.
CDMO expansion, microneedle technology, and overseas market development in China, the Middle East, and Latin America remain at an early stage with limited revenue contribution so far.
The domestic OTC-centered business structure supports stable cash flow but also acts as a factor constraining the ceiling for top-line growth.
Investors will need to track future earnings releases and the progress of new businesses together to assess both the durability of the profit improvement and the actual results of growth-driver diversification. This report is for informational purposes only and does not constitute a buy or sell recommendation.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.